Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 76
Filter
1.
Phytochemistry ; 183: 112641, 2021 Mar.
Article in English | MEDLINE | ID: mdl-33421890

ABSTRACT

Karanjin [IUPAC: 3-methoxy-2-phenylfuro-(2,3-h-chrome-4-ol)], a bioactive furanoflavonoid and a potent biomolecule, was first isolated from Pongamia pinnata (L.). The crude extracts from root, leaf and seed having active constituent karanjin is highly valued in both traditional and modern knowledge systems. This review highlights, critically assesses, and presents the probable biosynthetic pathways of karanjin and its isolation methodologies with a view to actualizing its full potential. Karanjin exhibits multiple health benefits and applications, with evident anti-diabetic, anti-cancer, anti-inflammatory, anti-hyperglycemic, antioxidant, anti-colitis, anti-ulcer, and anti-Alzheimer properties. Consequently, the physiochemical properties and biological effects of karanjin have been detailed and analyzed. The efficacy of karanjin has been attenuated by toxicological studies that have proven karanjin to be non-toxic at physiological conditions as substantiated by in vitro and in vivo studies. In addition, the multiple insect repellent/insecticidal properties of karanjin and its availability as an acaricide/bio-insecticide have been reviewed. This review article underscores and endorses the immense potential for novel drug leads in various medicinal and industrial applications, suggesting a deeper insight into its metabolic fate, bioavailability, and cellular effects that await further investigations.


Subject(s)
Benzopyrans , Millettia , Anti-Inflammatory Agents , Seeds
2.
J Dent Res ; 98(6): 713-719, 2019 06.
Article in English | MEDLINE | ID: mdl-30958728

ABSTRACT

Chronic inflammation of the salivary glands from pathologic conditions such as Sjögren's syndrome can result in glandular destruction and hyposalivation. To understand which molecular factors may play a role in clinical cases of salivary gland hypofunction, we developed an aquaporin 5 (AQP5) Cre mouse line to produce genetic recombination predominantly within the acinar cells of the glands. We then bred these mice with the TNF-αglo transgenic line to develop a mouse model with salivary gland-specific overexpression of TNF-α; which replicates conditions seen in sialadenitis, an inflammation of the salivary glands resulting from infection or autoimmune disorders such as Sjögren's syndrome. The resulting AQP5-Cre/TNF-αglo mice display severe inflammation in the salivary glands with acinar cell atrophy, fibrosis, and dilation of the ducts. AQP5 expression was reduced in the salivary glands, while tight junction integrity appeared to be disrupted. The immune dysregulation in the salivary gland of these mice led to hyposalivation and masticatory dysfunction.


Subject(s)
Sialadenitis/genetics , Tumor Necrosis Factor-alpha/genetics , Animals , Female , Humans , Mice , Mice, Transgenic , Salivary Glands/physiopathology , Sjogren's Syndrome
3.
Am J Transplant ; 18(10): 2465-2472, 2018 10.
Article in English | MEDLINE | ID: mdl-29451354

ABSTRACT

Kidney Donor Risk Index (KDRI) introduced in 2009 included hepatitis C serologic but not viremic status of the donors. With nucleic acid amplification testing (NAT) now being mandatory, further evaluation of these donors is possible. We conducted a retrospective matched case-control analysis of adult deceased donor kidney transplants performed between December 5, 2014 to December 31, 2016 with the KDRI score and hepatitis C virus antibody (HCV Ab) and NAT testing status obtained from the United Network for Organ Sharing database. The 205 aviremic HCV Ab+ NAT - kidney transplants were compared to KDRI matched control kidneys that were HCV Ab-NAT-. The aviremic HCV kidneys were recovered from donors who were significantly younger, more likely to be white, and less likely to have hypertension and diabetes. The majority of the recipients of the aviremic HCV kidneys when compared to matched controls were HCV positive: 90.2% vs 4.3%. The recipients were significantly older, were on dialysis for a shorter time, and were transplanted sooner. The graft survival of aviremic HCV kidneys was similar (P < .08). If the HCV status of the aviremic kidneys was assumed to be negative, 122 more kidneys could have been allocated to patients with estimated posttransplant survival <20. Seven kidneys would no longer have Kidney Donor Profile Index >85%. Further policies might consider these findings to appropriately allocate these kidneys.


Subject(s)
Graft Survival , Hepatitis C/diagnosis , Kidney Failure, Chronic/mortality , Kidney Transplantation/mortality , Risk Assessment/methods , Tissue Donors/supply & distribution , Tissue and Organ Procurement/statistics & numerical data , Adult , Case-Control Studies , Decision Making , Female , Follow-Up Studies , Hepacivirus/genetics , Hepacivirus/isolation & purification , Hepatitis C/transmission , Hepatitis C/virology , Hepatitis C Antibodies/blood , Humans , Kidney/virology , Kidney Failure, Chronic/surgery , Male , Middle Aged , Prognosis , Prospective Studies , Quality Control , Risk Factors , Survival Rate
4.
Transplant Proc ; 50(1): 14-19, 2018.
Article in English | MEDLINE | ID: mdl-29407297

ABSTRACT

BACKGROUND: The new kidney allocation system (KAS) intends to allocate the top 20% of kidneys to younger recipients with longer life expectancy. We hypothesized that the new KAS would lead to greater allocation of Public Health Service (PHS) increased-risk donor organs to younger recipients. METHODS: Analyses of the Organ Procurement and Transplantation Network data of patients who underwent primary deceased kidney transplantation were performed in pre- and post-KAS periods. RESULTS: The allocation of PHS increased-risk kidney allografts in various age groups changed significantly after implementation of the new KAS, with an increased proportion of younger individuals receiving increased-risk kidneys (7% vs 10% in age group 20-29 y and 13% vs 18% in age group 30-39 y before and after KAS, respectively; P < .0001). This trend was reversed in recipients 50-59 years old, with 31% in the pre-KAS period compared with 26% after KAS (P < .0001). CONCLUSIONS: The new KAS resulted in a substantial increase in allocation of PHS increased-risk kidneys to candidates in younger age groups. Because increased-risk kidneys are generally underutilized, future efforts to optimize the utilization of these organs should target younger recipients and their providers.


Subject(s)
Kidney Transplantation/statistics & numerical data , Tissue Donors/supply & distribution , Tissue and Organ Procurement/methods , Transplants/statistics & numerical data , Adult , Age Factors , Aged , Female , Humans , Kidney Transplantation/standards , Male , Middle Aged , Risk Factors , Transplants/standards
5.
Am J Transplant ; 17(11): 2863-2868, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28688205

ABSTRACT

Previous studies have grouped all donors positive for hepatitis C virus (HCV) antibody (Ab). Only recently has donor HCV nucleic acid testing (NAT) become routine, and the impact of Ab and NAT status on organ utilization is unknown. Using the United Network for Organ Sharing database, we identified 9290 donors from 2015 to 2016 for whom both HCV Ab and NAT data were available and compared organ utilization by HCV status. Overall, 93.8% of donors were Ab negative and NAT negative (Ab-NAT-), 0.15% were Ab negative and NAT positive, 1.8% were Ab positive and NAT negative (Ab+NAT-), and 4.2% were both Ab and NAT positive (Ab+NAT+). Ab-NAT- donors donated at the highest rate for all organs except livers, of which Ab+NAT- donors donated at a higher rate (81.2% vs 73.2%, p = 0.03). Livers were discarded for reasons related to abnormal biopsies in Ab+NAT+ donors, whereas kidneys from Ab- or NAT-positive donors were discarded for reasons related to HCV status. Using a propensity score-matched model, we estimated that using Ab+NAT- donors at the same rate as Ab-NAT- donors could result in 48 more kidney donors, 37 more heart donors, and 15 more lung donors annually. We urge the use of HCV Ab+NAT- donors for appropriately selected and consenting recipients.


Subject(s)
Hepacivirus/genetics , Hepatitis C/diagnosis , Nucleic Acid Amplification Techniques/methods , Nucleic Acids/analysis , Organ Transplantation , Tissue Donors , Tissue and Organ Harvesting/statistics & numerical data , Adolescent , Adult , Child , Child, Preschool , Decision Making , Female , Follow-Up Studies , Hepacivirus/immunology , Hepatitis C/genetics , Hepatitis C/transmission , Humans , Infant , Infant, Newborn , Male , Mass Screening , Middle Aged , Prognosis , Retrospective Studies , Young Adult
6.
Epidemiol Infect ; 145(5): 857-863, 2017 04.
Article in English | MEDLINE | ID: mdl-28065212

ABSTRACT

One case of hospital-acquired listeriosis was linked to milkshakes produced in a commercial-grade shake freezer machine. This machine was found to be contaminated with a strain of Listeria monocytogenes epidemiologically and molecularly linked to a contaminated pasteurized, dairy-based ice cream product at the same hospital a year earlier, despite repeated cleaning and sanitizing. Healthcare facilities should be aware of the potential for prolonged Listeria contamination of food service equipment. In addition, healthcare providers should consider counselling persons who have an increased risk for Listeria infections regarding foods that have caused Listeria infections. The prevalence of persistent Listeria contamination of commercial-grade milkshake machines in healthcare facilities and the risk associated with serving dairy-based ice cream products to hospitalized patients at increased risk for invasive L. monocytogenes infections should be further evaluated.


Subject(s)
Cross Infection/epidemiology , Environmental Microbiology , Food Handling , Foodborne Diseases/epidemiology , Listeria monocytogenes/isolation & purification , Listeriosis/epidemiology , Cross Infection/microbiology , Female , Foodborne Diseases/microbiology , Genotype , Hospitals , Humans , Listeria monocytogenes/classification , Listeria monocytogenes/genetics , Listeriosis/microbiology , Male , Middle Aged , Molecular Typing
7.
Transpl Infect Dis ; 18(3): 372-80, 2016 Jun.
Article in English | MEDLINE | ID: mdl-27004439

ABSTRACT

BACKGROUND: Gastrointestinal (GI) cytomegalovirus (CMV) disease is the most common manifestation of tissue-invasive CMV infection in solid organ transplant (SOT) recipients, but the diagnostic yields of blood and tissue testing have not been systematically assessed in a large patient cohort. METHODS: We retrospectively identified consecutive SOT recipients with biopsy-confirmed GI CMV disease who had both tissue and blood (CMV polymerase chain reaction or antigenemia) diagnostic testing performed within 14 days of diagnosis. Descriptive statistics and logistic regression were used to assess the association between patient factors and viremia and the diagnostic yield of tests performed on biopsy specimens. RESULTS: A total of 101 patients (73% donor seropositive/recipient seronegative [D+/R-], 22% recipient seropositive [R+]) had GI CMV disease (58% upper, 22% lower, and 20% both) at a median of 185 days (range, 21-6345 days) post transplant. In multivariate analysis, R+ CMV serostatus (odds ratio [OR] 0.1 [0.0-0.4], P < 0.001) and diagnosis >6 months post transplant (OR 0.3 [0.1-0.9], P = 0.03) were each independently associated with absence of CMV viremia at time of diagnosis. In the subset of patients (n = 29) in whom both histopathology and viral culture were performed on biopsy specimens, 11 (39%) had CMV detected only by culture and had similar clinical characteristics and outcomes to those with positive histopathology (P > 0.05 for all comparisons). CONCLUSIONS: The sensitivity of viremia in SOT recipients with GI CMV disease is significantly lower in CMV-seropositive patients and in those >6 months post transplant. Addition of viral culture to endoscopic biopsy specimens significantly increases the diagnostic yield for GI CMV disease.


Subject(s)
Cytomegalovirus Infections/diagnosis , Cytomegalovirus/immunology , Gastrointestinal Diseases/diagnosis , Organ Transplantation/adverse effects , Adult , Aged , Biopsy , Cytomegalovirus/genetics , Cytomegalovirus Infections/virology , Female , Gastrointestinal Diseases/virology , Humans , Male , Middle Aged , Retrospective Studies , Sensitivity and Specificity , Viremia , Young Adult
9.
Am J Transplant ; 14(12): 2758-64, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25376267

ABSTRACT

Invasive fungal infections (IFIs) are a common complication in liver transplant recipients. There are no previous randomized trials of an echinocandin for the prevention of IFIs in solid organ transplant recipients. In a randomized, double-blind trial conducted at University-affiliated transplant centers, 200 high-risk liver transplant recipients (100 patients per group) received either anidulafungin or fluconazole for antifungal prophylaxis. Randomization was stratified by Model for End-Stage Liver Disease score ≥30 and receipt of a pretransplant antifungal agent. The primary end point was IFI in a modified intent-to-treat analysis. The overall incidence of IFI was similar for the anidulafungin (5.1%) and the fluconazole groups (8.0%) (OR 0.61, 95% CI 0.19-1.94, p = 0.40). However, anidulafungin prophylaxis was associated with less Aspergillus colonization or infection (3% vs. 9%, p = 0.08), lower breakthrough IFIs among patients who had received pretransplant fluconazole (0% vs. 27%, p = 0.07), and fewer cases of antifungal resistance (no cases vs. 5 cases). Both drugs were well-tolerated. Graft rejection, fungal-free survival, and mortality were similar for both groups. Thus, anidulafungin and fluconazole have similar efficacy for antifungal prophylaxis in most liver transplant recipients. Anidulafungin may be beneficial if the patient has an increased risk for Aspergillus infection or received fluconazole before transplantation.


Subject(s)
Antibiotic Prophylaxis , Echinocandins/therapeutic use , Fluconazole/therapeutic use , Graft Rejection/epidemiology , Liver Diseases/complications , Liver Transplantation/adverse effects , Mycoses/prevention & control , Adolescent , Adult , Aged , Anidulafungin , Antifungal Agents/therapeutic use , Double-Blind Method , Female , Follow-Up Studies , Graft Rejection/microbiology , Graft Rejection/mortality , Graft Survival , Humans , Immunocompromised Host , Incidence , Liver Diseases/microbiology , Liver Diseases/surgery , Male , Middle Aged , Mycoses/epidemiology , Mycoses/microbiology , Postoperative Complications , Prognosis , Risk Factors , Survival Rate , Transplant Recipients , United States/epidemiology , Young Adult
10.
Pak J Biol Sci ; 16(2): 86-91, 2013 Jan 15.
Article in English | MEDLINE | ID: mdl-24199492

ABSTRACT

The problem of metalnutrient deficiency is becoming more serious with the introduction of modern agricultural practices. As a result, metalnutrient deficiency is recognized as one of the critical yield limiting factors. Metalnutrients are generally offered in their sulphate or oxide forms. However, it is reported that organically bound minerals generally have a higher bioavailability than inorganic minerals. Chelation makes otherwise unavailable metalnutrients plant available. Amino acids are well known among various chelating agents. In present investigation the fungus Paecilomyces variotii PR-4 was isolated from soil and was used for production of protease and determination of its activity. Proteins from germinating seeds of chick pea, mung bean, soybean and cowpea were hydrolyzed for the production of amino acids. Amino acids were recovered, estimated and utilized for chelation of metalnutrients viz., Zn, Cu, Fe, Mn, Mg, B and Mo. The resultant chelates were employed to detect with Fourier Transform Infra-Red Spectrophotometer (FTIR) analysis. The peaks of most intensive bands in the IR spectra of ligands recorded were present in the intervals of the wave numbers 3500-3300 and 1720-1700 cm(-1). Chelation of metalnutrients led to the broadening of peak and changes of the peak position of hydroxyl groups, which indicated the binding of the carboxylic groups and primary amine groups of amino acids to the metalnutrients. The resultant amino acids-metalnutrient chelates can be utilized as organic fertilizer.


Subject(s)
Amino Acids/metabolism , Chelating Agents/metabolism , Fabaceae/metabolism , Paecilomyces/metabolism , Peptide Hydrolases/biosynthesis , Plant Proteins/metabolism , Seeds/metabolism , Fabaceae/embryology , Spectroscopy, Fourier Transform Infrared
12.
Am J Transplant ; 13 Suppl 3: 55-66; quiz 66, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23347214

ABSTRACT

Varicella zoster virus (VZV) and the two herpes simplex viruses (HSV) are human α-herpesviruses that establish life-long latency in neural ganglia after initial primary infection. In the solid organ transplant (SOT) population, manifestations of VZV or HSV may be seen in up to 70% of recipients if no prophylaxis is used, some of them life and organ threatening. While there are effective vaccines to prevent VZV primary infection and reactivation in immunocompetent adults, these vaccines are contraindicated after SOT because they are live-virus vaccines. For HSV, prevention has focused primarily on antiviral strategies because the immunologic correlates of protection and control are different from VZV, making vaccine development more challenging. Current antiviral therapy remains effective for the majority of clinical VZV and HSV infections.


Subject(s)
Chickenpox/complications , Herpes Simplex/complications , Herpesvirus 3, Human/metabolism , Organ Transplantation/adverse effects , Simplexvirus/metabolism , Adult , Antiviral Agents/therapeutic use , Chickenpox/etiology , Child , Drug Resistance, Viral , Ganglia/metabolism , Herpes Simplex/etiology , Humans , Risk Factors , Treatment Outcome
13.
Transpl Infect Dis ; 15(1): E28-32, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23279859

ABSTRACT

Parainfluenza virus (PIV) may cause life-threatening pneumonia in lung transplant patients and there are no proven effective therapies. We report the use of inhaled DAS181, a novel sialidase fusion protein, to treat severe PIV type 3 pneumonia in a lung transplant patient. Treatment was well tolerated and associated with improvement in oxygenation and symptoms, along with rapid clearance of PIV. DAS181 should be systematically evaluated for treatment of PIV infection in transplant recipients.


Subject(s)
Antiviral Agents/therapeutic use , Lung Transplantation/adverse effects , Parainfluenza Virus 3, Human/isolation & purification , Pneumonia, Viral/drug therapy , Recombinant Fusion Proteins/therapeutic use , Respirovirus Infections/drug therapy , Female , Humans , Middle Aged , Pneumonia, Viral/etiology , Respirovirus Infections/etiology , Severity of Illness Index , Treatment Outcome
14.
Adv Mater ; 25(10): 1499-503, 2013 Mar 13.
Article in English | MEDLINE | ID: mdl-23293091

ABSTRACT

Active control over the assembly of colloidal and nanoparticles has important applications for the design of new nanostructured materials, but it is a difficult task. Here, a new method is presented to control the morphology of colloidal aggregates using critical Casimir forces. Via direct temperature control of critical Casimir forces, the particles are assembled into aggregates with well-defined architecture.

15.
Aliment Pharmacol Ther ; 37(1): 91-7, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23094860

ABSTRACT

BACKGROUND: Sorafenib is currently the only approved systemic therapy shown to have efficacy in the treatment of advanced hepatocellular carcinoma (HCC). Recent studies suggest that hepatitis C (HCV)-related HCC patients derive more clinical benefit from sorafenib than other subgroups, but the mechanism for this effect is unknown. In vitro data suggest that sorafenib may exert anti-viral properties, and thus our aim in this study was to evaluate potential anti-viral activity of sorafenib in patients with HCV-related HCC. AIM: To evaluate potential anti-viral activity of sorafenib in patients with HCV-related HCC. METHODS: We prospectively enrolled patients with HCV-related HCC treated with sorafenib for up to 6 months. Baseline clinical, viral and oncologic data were collected. Patients' HCV viral loads were obtained at various time points, and compared with their baseline viral levels. No patients received any known anti-viral therapy during this time. RESULTS: Thirty-three patients were identified with baseline and subsequent HCV levels available for analysis. Six patients completed 6 months of full dose sorafenib, and comparisons of their HCV viral loads showed no significant change at week 24 (difference of means = 0.3500, CI: -0.1799-0.8799, P = 0.150), or the interim time points. Similarly, the HCV viral loads of all patients who received sorafenib and the viral loads of those patients who had tumour response to sorafenib showed no significant changes at any time point. CONCLUSION: Despite preclinical data and previous subgroup analyses suggesting that sorafenib has an anti-viral effect against HCV, this study suggests that sorafenib lacks significant anti-viral activity in HCV patients with HCC.


Subject(s)
Antineoplastic Agents/therapeutic use , Carcinoma, Hepatocellular/drug therapy , Hepatitis C/drug therapy , Liver Neoplasms/drug therapy , Niacinamide/analogs & derivatives , Phenylurea Compounds/therapeutic use , Aged , Aged, 80 and over , Carcinoma, Hepatocellular/virology , Cohort Studies , Female , Hepatitis C/virology , Humans , Liver Neoplasms/virology , Male , Middle Aged , Niacinamide/therapeutic use , Sorafenib , Treatment Outcome , Viral Load
16.
Am J Transplant ; 12(11): 3021-30, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22947426

ABSTRACT

Maribavir is an oral benzimidazole riboside with potent in vitro activity against cytomegalovirus (CMV), including some CMV strains resistant to ganciclovir. In a randomized, double-blind, multicenter trial, the efficacy and safety of prophylactic oral maribavir (100 mg twice daily) for prevention of CMV disease were compared with oral ganciclovir (1000 mg three times daily) in 303 CMV-seronegative liver transplant recipients with CMV-seropositive donors (147 maribavir; 156 ganciclovir). Patients received study drug for up to 14 weeks and were monitored for CMV infection by blood surveillance tests and also for the development of CMV disease. The primary endpoint was Endpoint Committee (EC)-confirmed CMV disease within 6 months of transplantation. In a modified intent-to-treat analysis, the noninferiority of maribavir compared to oral ganciclovir for prevention of CMV disease was not established (12% with maribavir vs. 8% with ganciclovir: event rate difference of 0.041; 95% CI: -0.038, 0.119). Furthermore, significantly fewer ganciclovir patients had EC-confirmed CMV disease or CMV infection by pp65 antigenemia or CMV DNA PCR compared to maribavir patients at both 100 days (20% vs. 60%; p < 0.0001) and at 6 months (53% vs. 72%; p = 0.0053) after transplantation. Graft rejection, patient survival, and non-CMV infections were similar for maribavir and ganciclovir patients. Maribavir was well-tolerated and associated with fewer hematological adverse events than oral ganciclovir. At a dose of 100 mg twice daily, maribavir is safe but not adequate for prevention of CMV disease in liver transplant recipients at high risk for CMV disease.


Subject(s)
Antiviral Agents/administration & dosage , Benzimidazoles/administration & dosage , Cytomegalovirus Infections/drug therapy , Graft Rejection/prevention & control , Liver Transplantation/methods , Ribonucleosides/administration & dosage , Acyclovir/administration & dosage , Administration, Oral , Cytomegalovirus Infections/diagnosis , Dose-Response Relationship, Drug , Double-Blind Method , Drug Administration Schedule , Female , Follow-Up Studies , Ganciclovir/administration & dosage , Graft Rejection/virology , Graft Survival , Humans , Liver Transplantation/adverse effects , Liver Transplantation/immunology , Male , Postoperative Complications/drug therapy , Postoperative Complications/virology , Prospective Studies , Risk Assessment , Treatment Outcome
18.
Phys Rev E Stat Nonlin Soft Matter Phys ; 83(6 Pt 1): 061607, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21797380

ABSTRACT

We study random sequential adsorption (RSA) of coupled three-circle objects (consisting of two circular discs of radius r(2) touching the central one of radius r(1) making an angle θ) on a two-dimensional continuum substrate. For all the objects corresponding to various values of radius ratios r(2)/r(1) and angles θ, approach of instantaneous coverage Θ(t) to the jammed state coverage Θ(∞), is found to obey a power law Θ(∞)-Θ(t)~t(-p), as expected based on general arguments. However, the observed values of exponent p and jammed state coverage Θ(∞) are found to vary with r(2)/r(1) and θ. The interplay between the degree of nonconvexity |δ| and packing efficiency η of the object governs the saturation coverage Θ(∞).

19.
Transpl Infect Dis ; 13(3): 244-9, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21414119

ABSTRACT

BACKGROUND: Cytomegalovirus (CMV) disease occurs frequently after cessation of antiviral prophylaxis in CMV-seronegative kidney transplant recipients from seropositive donors (D+R-), and the risk factors are incompletely defined. METHOD: We retrospectively assessed the incidence, clinical features, and risk factors for CMV disease in a cohort of D+R- kidney transplant recipients who received antiviral prophylaxis at a single US transplant center using descriptive statistics and Cox proportional hazards models. RESULTS: CMV disease developed in 29 of 113 (26%) D+R- patients at a median of 185 days (interquartile range 116-231 days) post transplant, including CMV syndrome (66%) and tissue invasive disease (34%). The incidence of CMV disease was higher in patients who underwent re-transplantation (57% vs. 24%) and this factor was independently associated with a higher risk of CMV disease in multivariable analysis (hazard ratio, 4.02; 95% confidence interval, 1.3-13; P = 0.016). Other demographic and transplant variables were not independently associated with a risk of late-onset CMV disease. CONCLUSIONS: Despite a comprehensive analysis of patient and transplant variables, only re-transplantation was identified as a risk factor for CMV disease in D+R- kidney transplant recipients who received antiviral prophylaxis, but had limited clinical predictive value. The development of novel laboratory markers to identify patients at greatest risk for CMV disease should be a priority for future studies.


Subject(s)
Antibodies, Viral/blood , Antiviral Agents/therapeutic use , Cytomegalovirus Infections/epidemiology , Ganciclovir/therapeutic use , Kidney Transplantation/adverse effects , Tissue Donors , Adult , Chemoprevention , Cytomegalovirus/immunology , Cytomegalovirus Infections/diagnosis , Cytomegalovirus Infections/prevention & control , Cytomegalovirus Infections/virology , Female , Humans , Incidence , Male , Middle Aged , Proportional Hazards Models , Risk Factors , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...